Mass General Brigham, Inc Jounce Therapeutics, Inc. Transaction History

Mass General Brigham, Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 27, 2022	SELL	$2.8 - $7.67 $58,679 - $160,740	-20,957 Closed	0 $0
Q1 2022 Apr 15, 2022	BUY	$6.01 - $8.54 $125,951 - $178,972	20,957 New	20,957 $1,000
Q3 2021 Oct 08, 2021	SELL	$5.04 - $8.73 $97,226 - $168,410	-19,291 Closed	0 $0
Q2 2021 Jul 19, 2021	BUY	$6.58 - $10.66 $126,934 - $205,642	19,291 New	19,291 $131,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Mass General Brigham, Inc, based on Form 13F filings with the SEC.

Stay updated on Mass General Brigham, Inc with notifications on news.